Athersys, Inc.
http://www.athersys.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Athersys, Inc.
Healios, Athersys Confident Despite Missed Japan Stroke Endpoint
A missed primary endpoint in new top-line results from a Japanese trial with the stem cell therapy for stroke MultiStem hits Athersys and Japanese partner hard, casting a shadow over ongoing studies.
Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
GNT Eyes Unmet Need As Novel Ischemic Stroke Therapy Moves To Phase III
Korea's GNT Pharma is set to take its first-in-class, multi-targeted stroke therapy Nelonemdaz into Phase III, raising hopes for a new treatment that could sharply reduce disabilities and death in stroke patients.
Eight Themes That Will Shape Biopharma In Transformational 2021
A year after COVID-19 first turned the world upside down, executives across the biopharma industry consider what 2021 holds in store. The impact of the pandemic will have profound and long-lasting implications for a sector that has been at the heart of responding to the global health challenge.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- BTHC VI Inc.